Quantcast
Channel: The Life Sciences Blog
Browsing all 15 articles
Browse latest View live

CTI closes in on spinoff plans

In March, Cell Therapeutics said it hoped to spin off parts of the company's Systems Medicine subsidiary and its operations in Bresso, Italy, in order to create a new company that would allow drug...

View Article



CellCyte Genetics may shut down

CellCyte Genetics, the Bothell stem cell company, says it does not have enough cash to fund its operations beyond the next month and has stopped paying its employees.

View Article

PATH to fund vaccine research at biotech

PATH, the Seattle-based global health non-profit, said today it would fund preclinical research at a Missoula, Mont., biotech, which is developing vaccine candidates against Shigella bacteria that can...

View Article

Ekos hopes to cash in on new guidelines

My story in Wednesday's paper

View Article

Sonus shareholders approve merger

Sonus Pharmaceuticals said today that its shareholders had overwhelmingly approved the company's merger with Vancouver, B.C.-based OncoGenex Technologies.

View Article


Another Seattle biotech faces delisting

Oncothyreon said Wednesday it had received a notice from the Nasdaq Stock Market saying that it was not in compliance with a requirement that its market value be at least $50 million.

View Article

OncoGenex lays off 21 employees here

I updated this post with information from an interview with OncoGenex's CEO

View Article

Mid-day round-up: OncoGenex, Amgen

Amgen said this morning that Nplate, its treatment for Idiopathic thrombocytopenic purpura, a rare bleeding disorder, has been approved by the FDA. Read a release here. The approval was expected,...

View Article


Top stories to follow during the rest of 2008

Next week is the last for the blog.

View Article


Stories to watch: The comeback companies

Second in a series on the blog looking at stories to watch during the coming months

View Article

Round-up: Cell Therapeutics, Amgen

I was off Monday, so here are two stories I missed.

View Article

Stories to watch: Amgen’s Elliott Bay plans

Third in a series on the blog looking at stories to watch during the coming months

View Article

Stories to watch: Provenge

Fourth in a series on the blog looking at stories to watch during the coming months

View Article


Round-up: Dendreon, SonoSite

A day after rival Cell Genesys halted a trial of its prostate cancer drug due to safety questions, Dendreon's stock actually inched up 1.4 percent. Some reports appeared to suggest that Cell Genesys'...

View Article

Stories to watch: ZGEN and SGEN

[Note: My time at the Seattle Post-Intelligencer is up, so this blog is no longer being updated. Please e-mail margaretsantjer@seattlepi.com with any life sciences related story ideas or news]

View Article

Browsing all 15 articles
Browse latest View live




Latest Images